Liver cancer rarely gets the attention that breast, oral, or cervical cancer do in India's public health conversation — yet nearly 35,000 Indians are diagnosed with it every year, and almost as many die from it. Most of these patients never had a symptom until the disease was already advanced, because the organ most responsible for filtering their blood can lose up to 75% of its function before it starts sending out warning signs. For families managing hepatitis B, hepatitis C, or fatty liver disease at home, understanding this cancer — and knowing which six-monthly test can catch it early — can be the difference between a curable tumour and a terminal one.
This guide explains what hepatocellular carcinoma (HCC), the most common form of liver cancer, means for Indian patients: why it happens, who is at risk, how doctors find it, and what treatment actually costs and covers in 2026.
Liver Cancer in India: The Numbers
Liver cancer is now India's eighth most common cancer overall, with an incidence rate of roughly 2.15 per 100,000 people and close to 34,000–35,000 deaths recorded annually — a mortality rate nearly as high as the incidence rate, which tells you how late most cases are caught. According to Indian Council of Medical Research (ICMR) population-based cancer registry data, the age-adjusted incidence among men ranges from 0.7 to 7.5 per 100,000 and among women from 0.2 to 2.2 per 100,000, giving a male-to-female ratio of roughly 4:1.
Geography matters a great deal. The northeastern states — particularly Mizoram, Manipur, and parts of Assam — have historically recorded the highest HCC rates in the country, linked to high rates of chronic hepatitis B and dietary aflatoxin exposure. More recently, Gujarat, Maharashtra, Goa, and Kerala have emerged as fast-growing hotspots, a shift researchers link to rising obesity, diabetes, and alcohol-associated fatty liver disease rather than viral hepatitis alone.
Perhaps the most striking recent finding: liver cancer mortality is rising faster among Indian women than men, even though absolute numbers remain higher in men — a trend tracked to increasing rates of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD) in women.
What Causes Liver Cancer?
More than 90% of hepatocellular carcinoma develops in a liver that is already scarred by cirrhosis. Understanding the road to cirrhosis is therefore the key to understanding liver cancer risk.
Chronic Hepatitis B and C
For decades, chronic hepatitis B was India's leading cause of HCC, and it remains a major driver, particularly in the northeast and among people infected at birth or in early childhood (India introduced the hepatitis B birth-dose vaccine nationally only in 2011, so anyone born earlier may be unvaccinated). Chronic hepatitis C, often acquired through unsafe injections, unscreened blood transfusions, or shared needles, is a second major viral cause. Both infections silently inflame the liver for years before symptoms appear. See our detailed guides on hepatitis B and hepatitis C for testing and treatment specifics — hepatitis C, notably, is now curable in 8–12 weeks with oral direct-acting antivirals, which sharply cuts future cancer risk if caught early.
Fatty Liver Disease (MASLD/NAFLD)
The single biggest shift in Indian liver cancer over the past decade is the rise of MASLD, associated with obesity, type 2 diabetes, and metabolic syndrome. Recent Indian data shows MASLD now accounts for over a third of HCC cases, having overtaken viral hepatitis as the single largest contributor. Because roughly 1 in 3 urban Indian adults has some degree of fatty liver, and India's diabetes burden exceeds 10 crore adults, this is a rapidly growing risk pool. Read more in our fatty liver disease guide and diabetes management guide.
Alcohol
Sustained heavy alcohol use causes alcohol-related cirrhosis, which independently raises HCC risk. Alcohol and MASLD frequently coexist and multiply each other's damage.
Aflatoxin Exposure
A distinctly Indian and South Asian risk factor: aflatoxins, toxins produced by mould that contaminates poorly stored groundnuts, maize, and other grains, especially during humid monsoon storage. Chronic dietary aflatoxin exposure, particularly combined with hepatitis B infection, dramatically multiplies liver cancer risk. Buying groundnuts and grains from reputable sources, discarding visibly mouldy stock, and storing grains in dry, ventilated conditions are simple but meaningful precautions.
Cirrhosis From Any Cause
Whatever the original insult — viral, alcohol, metabolic, or the rarer autoimmune and genetic liver diseases — once cirrhosis develops, the annual risk of HCC is roughly 2–5%, which is why cirrhotic patients require lifelong monitoring. See our liver cirrhosis guide for staging and management.
Symptoms: Why Liver Cancer Hides So Well
The liver has enormous reserve capacity, so early tumours typically cause no symptoms at all. When symptoms do appear, they often signal that the disease has progressed or that the underlying liver has decompensated:
- Dull ache or fullness in the upper right abdomen, sometimes radiating to the right shoulder
- Unexplained weight loss and loss of appetite
- New or worsening jaundice — yellowing of the eyes and skin, dark urine
- Abdominal swelling (ascites) — fluid build-up in the belly
- Easy bruising or bleeding, since the liver makes clotting factors
- A new lump or firmness felt below the right ribs
- Sudden decompensation in a known cirrhotic patient — new confusion, worsening jaundice, or fresh ascites in someone whose liver disease had been stable is a red flag that always warrants urgent imaging
- General fatigue and weakness
Because these symptoms overlap heavily with ordinary cirrhosis, they are easy to dismiss — which is exactly why scheduled screening, not waiting for symptoms, is the strategy doctors rely on for high-risk patients.
Screening: The Test That Actually Saves Lives
Unlike many cancers, liver cancer has a well-defined, cost-effective screening protocol for people who are already known to be at risk. The Indian National Association for Study of the Liver (INASL) and international bodies recommend:
- Six-monthly abdominal ultrasound, with or without a blood test called Alpha-Fetoprotein (AFP), for anyone with cirrhosis (regardless of cause) and for chronic hepatitis B carriers, even without cirrhosis, especially if they have a family history of liver cancer or are over 40.
- AFP alone is not accurate enough for population screening — levels can be high in benign conditions and normal in up to 40% of early cancers — but tracked alongside ultrasound over time, a rising trend is a strong early warning sign.
- Newer blended protocols such as GALAD/GALAD-US, which combine AFP with other biomarkers and patient factors, are being studied in India and show meaningfully higher detection rates than ultrasound and AFP alone, though they are not yet universally available outside specialist centres.
If you or a family member has hepatitis B, hepatitis C, cirrhosis, or diagnosed fatty liver disease, ask your hepatologist or gastroenterologist whether you should be on a six-monthly surveillance schedule. Missing even one round of screening meaningfully raises the odds of catching a tumour only after it has grown past the point of cure.
Diagnosis: Confirming and Staging the Cancer
| Test | What it shows | Approx. cost (private, India) |
|---|---|---|
| Abdominal ultrasound | Initial detection of a liver mass | ₹800–2,000 |
| AFP blood test | Tumour marker, trend monitoring | ₹500–1,200 |
| Triple-phase / multiphase CT scan | Confirms characteristic HCC blood-flow pattern, staging | ₹6,000–15,000 |
| MRI with liver-specific contrast | More sensitive than CT for small lesions | ₹10,000–20,000 |
| Liver biopsy | Tissue confirmation when imaging is inconclusive | ₹5,000–12,000 |
| Liver function test (LFT) & Child-Pugh scoring | Assesses how well the remaining liver is functioning | ₹500–1,000 |
Unlike most solid cancers, HCC can sometimes be diagnosed on imaging alone — a lesion with the classic blood-flow pattern (rapid uptake of contrast followed by rapid washout) on a triple-phase CT or MRI in a cirrhotic liver is often diagnostic without a biopsy, following internationally recognised LI-RADS criteria. See our liver function test guide to understand what your LFT numbers mean for surgical fitness.
Treatment Options and Costs
Treatment depends heavily on tumour size, number, location, and — critically — how well the rest of the liver is functioning, since the liver must keep working after treatment.
Surgery and Transplant — The Curative Options
- Surgical resection: Removing the tumour along with a margin of healthy liver, suitable only for patients with well-preserved liver function and a single, resectable tumour. Cost: roughly ₹1–5 lakh in private centres.
- Liver transplantation: The most effective cure for patients who meet the Milan criteria (a single tumour up to 5 cm, or up to three tumours each under 3 cm, with no spread beyond the liver), because it treats both the cancer and the underlying cirrhosis simultaneously. Cost: roughly ₹20–28 lakh for a living-donor transplant, with annual post-transplant medication costing a further ₹1–2 lakh.
Locoregional Therapies — For Patients Who Cannot Have Surgery
- Transarterial Chemoembolization (TACE): Delivers chemotherapy directly into the blood vessels feeding the tumour while blocking its blood supply. Widely used across Indian tertiary centres. Cost: roughly ₹80,000–1.8 lakh per cycle, often needing 2–4 cycles.
- Transarterial Radioembolization (TARE): Delivers radioactive microspheres directly into the tumour's blood supply; used for larger or more complex tumours at specialised centres.
- Radiofrequency Ablation (RFA) / Microwave Ablation: Uses heat to destroy small tumours (typically under 3 cm) through a needle inserted under imaging guidance — a good option for patients unfit for surgery.
Systemic Therapy — For Advanced or Metastatic Disease
For cancer that has spread beyond the liver or cannot be controlled locally, targeted therapy and immunotherapy have transformed outcomes over the past five years. Combinations such as atezolizumab plus bevacizumab, and oral targeted drugs like sorafenib and lenvatinib, are now standard first-line options at major Indian oncology centres, extending survival meaningfully compared to older chemotherapy regimens, though access and cost remain a real barrier for many families.
Government and Insurance Coverage
Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) covers liver transplantation and several liver cancer treatments up to ₹5 lakh per family per year for eligible beneficiaries at empanelled hospitals — see our Ayushman Bharat guide for eligibility. Several states run additional top-up schemes, including the Delhi Arogya Kosh, Tamil Nadu's Chief Minister's Comprehensive Health Insurance Scheme, and Maharashtra's Mahatma Jyotiba Phule Jan Arogya Yojana, which can substantially reduce out-of-pocket costs for eligible families.
Prevention: What Actually Reduces Your Risk
- Get the hepatitis B vaccine if you haven't already — it is one of the few genuinely cancer-preventing vaccines available, and it is now part of India's universal immunisation programme for newborns.
- Get tested for hepatitis B and C at least once if you were born before 2011, have ever had a blood transfusion before 2001, or have a family history of liver disease — both are simple blood tests.
- Treat hepatitis C if you have it — modern oral therapy cures over 95% of cases in 8–12 weeks and dramatically cuts future cancer risk.
- Manage fatty liver, diabetes, and obesity proactively — weight loss of even 7–10% of body weight meaningfully improves fatty liver disease.
- Limit alcohol, especially if you already have any form of liver disease.
- Store grains and groundnuts properly, discard visibly mouldy food, and buy from reputable sources to reduce aflatoxin exposure.
- Stay on your six-monthly screening schedule if you are in a high-risk group — this single habit is the biggest lever for catching liver cancer early.
Living With a Liver Cancer Diagnosis
A liver cancer diagnosis, especially against a backdrop of cirrhosis, involves managing two conditions at once — the tumour and the liver disease underneath it. Families coordinating care across cities, hospitals, and specialists benefit enormously from having every ultrasound, AFP trend, CT report, and biopsy result in one accessible place. MedicalVault's report upload feature lets you store every scan and lab result as it comes in, while MedicalVault's trend tracking makes it easy to see whether AFP levels are rising or falling over successive screening visits — a detail that is easy to lose track of across multiple lab reports and hospital visits. When a sibling or adult child in another city needs to review reports before a transplant evaluation or a second opinion, family sharing means they see the same complete record instantly, without waiting for scanned attachments over email. If you have questions about how MedicalVault organises lab trends over time, our FAQ page has more detail.
Key Takeaways
- Liver cancer causes around 34,000–35,000 deaths in India annually, and most cases are diagnosed late because early tumours cause no symptoms.
- Over 90% of liver cancer arises in a liver already damaged by cirrhosis, most often from hepatitis B, hepatitis C, fatty liver disease (MASLD), or alcohol — with MASLD now the single largest cause in India.
- Aflatoxin-contaminated grains and groundnuts are a distinctly Indian risk factor, especially combined with hepatitis B infection.
- Anyone with cirrhosis or chronic hepatitis B should have six-monthly ultrasound screening, with or without an AFP blood test — this is the single most effective early-detection strategy available.
- Treatment ranges from surgical resection and liver transplant for early disease to TACE, TARE, ablation, and targeted immunotherapy for more advanced cases; Ayushman Bharat and several state schemes help offset the substantial costs.
- Hepatitis B vaccination, hepatitis C treatment, and managing diabetes and obesity are the most effective ways to lower your lifetime risk.
- Keeping every ultrasound, AFP result, and scan organised on MedicalVault helps your hepatologist spot trends early and makes it far easier for family members to stay involved in care decisions.